title: [Protein tyrosine kinase inhibitors in cancer therapy].
abstract: The tyrosine kinase inhibitors (TKI) are small molecules of low molecular weight that inhibit tyrosine kinases, enzymes responsible for the activation of signal transduction cascades. Currently, a number of TKI received approval in various cancers, while others are in clinical development process: TKI are specifically clinically active when they target a tyrosine kinase (TK) with constitutional activity subsequent to a mutation, being then a master-gene driving transformation and tumour progression. Already, this drug-family provides a major therapeutic weapon against cancer.
authors: Service d'oncologie médicale, institut national d'oncologie, CHU Ibn Sina, Rabat, Maroc. boutayebdr@yahoo.fr
authors: S
authors: S
authors: Boutayeb
authors: F Z
authors: FZ
authors: Zakkouri
authors: M
authors: M
authors: Aitelhaj
authors: M
authors: M
authors: Mesmoudi
authors: A
authors: A
authors: Boutayeb
authors: W
authors: W
authors: Boutayeb
authors: H
authors: H
authors: Mrabti
authors: H
authors: H
authors: Errihani
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases